1. Home
  2. NVG vs WVE Comparison

NVG vs WVE Comparison

Compare NVG & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen AMT-Free Municipal Credit Income Fund

NVG

Nuveen AMT-Free Municipal Credit Income Fund

HOLD

Current Price

$13.18

Market Cap

2.7B

Sector

Finance

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$13.64

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVG
WVE
Founded
1999
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.4B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
NVG
WVE
Price
$13.18
$13.64
Analyst Decision
Strong Buy
Analyst Count
0
16
Target Price
N/A
$30.56
AVG Volume (30 Days)
568.8K
3.8M
Earning Date
01-01-0001
03-03-2026
Dividend Yield
4.65%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$109,230,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16.10
P/E Ratio
N/A
N/A
Revenue Growth
N/A
103.75
52 Week Low
$9.68
$5.28
52 Week High
$12.21
$21.73

Technical Indicators

Market Signals
Indicator
NVG
WVE
Relative Strength Index (RSI) 73.57 48.95
Support Level $12.79 $12.70
Resistance Level $12.97 $14.56
Average True Range (ATR) 0.12 0.78
MACD 0.04 -0.02
Stochastic Oscillator 100.00 53.73

Price Performance

Historical Comparison
NVG
WVE

About NVG Nuveen AMT-Free Municipal Credit Income Fund

Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: